Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016–2019)
Yue Dong, Tong Zhao, Wei Ai, et al.
Expert Opinion on Therapeutic Patents (2019) Vol. 29, Iss. 11, pp. 871-879
Closed Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Update on the epidemiology, genetics, and therapeutic options of hyperuricemia.
Lijun Li, Yipeng Zhang, Changchun Zeng
PubMed (2020) Vol. 12, Iss. 7, pp. 3167-3181
Closed Access | Times Cited: 164
Membrane transporters in drug development and as determinants of precision medicine
Aleksandra Galetin, Kim L. R. Brouwer, Donald Tweedie, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 255-280
Closed Access | Times Cited: 94
Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase
Yanyu Chen, Zean Zhao, Yongmei Li, et al.
Phytomedicine (2020) Vol. 80, pp. 153374-153374
Open Access | Times Cited: 91
Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia
Haolu Sun, Yi-wan Wu, He-ge Bian, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 67
An atlas connecting shared genetic architecture of human diseases and molecular phenotypes provides insight into COVID-19 susceptibility
Liuyang Wang, Thomas J. Balmat, Alejandro L. Antonia, et al.
Genome Medicine (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 58
Recent advances in gout drugs
Cheng Shi, Ziting Zhou, Xiaowei Chi, et al.
European Journal of Medicinal Chemistry (2022) Vol. 245, pp. 114890-114890
Closed Access | Times Cited: 45
Agents for the Treatment of Gout: Current Advances and Future Perspectives
Xiaoyi Zeng, Yajing Liu, Yuxin Fan, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 21, pp. 14474-14493
Closed Access | Times Cited: 24
Structural Basis for Inhibition of Urate Reabsorption in URAT1
Junping Fan, Wenjun Xie, Han Ke, et al.
JACS Au (2025) Vol. 5, Iss. 3, pp. 1308-1319
Open Access | Times Cited: 1
Emerging Roles of the Human Solute Carrier 22 Family
Sook Wah Yee, Kathleen M. Giacomini
Drug Metabolism and Disposition (2021) Vol. 50, Iss. 9, pp. 1193-1210
Open Access | Times Cited: 54
The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics
Xinghong Wu, Chongge You
PeerJ (2022) Vol. 11, pp. e14554-e14554
Open Access | Times Cited: 36
Pharmacological evaluation of a novel skeleton compound isobavachin (4′,7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity
Zean Zhao, Jian Luo, Hui Liao, et al.
Bioorganic Chemistry (2023) Vol. 133, pp. 106405-106405
Closed Access | Times Cited: 21
Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability
Tong Zhao, Qing Meng, Zhuosen Sun, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 19, pp. 10829-10854
Closed Access | Times Cited: 49
Effect of Berberine on Hyperuricemia and Kidney Injury: A Network Pharmacology Analysis and Experimental Validation in a Mouse Model
Qiaoping Li, Ziwei Huang, Defu Liu, et al.
Drug Design Development and Therapy (2021) Vol. Volume 15, pp. 3241-3254
Open Access | Times Cited: 36
Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability
Tong Zhao, Jian Zhang, Yucen Tao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 5, pp. 4218-4237
Closed Access | Times Cited: 24
Insoluble Fiber in Barley Leaf Attenuates Hyperuricemic Nephropathy by Modulating Gut Microbiota and Short-Chain Fatty Acids
Yongmei Li, Lu Li, Jinhong Tian, et al.
Foods (2022) Vol. 11, Iss. 21, pp. 3482-3482
Open Access | Times Cited: 22
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)
Xiaoyu Shi, Tong Zhao, Edeildo Ferreira da Silva‐Júnior, et al.
Expert Opinion on Therapeutic Patents (2022) Vol. 32, Iss. 12, pp. 1175-1184
Closed Access | Times Cited: 22
Design, synthesis and biological evaluation of 2-[1-(pyridin-2-ylmethyl)-1H-pyrazole-3-carboxamido]benzoic acids as promising urate transporter 1 inhibitors with potential nephroprotective efficacy for the treatment of hyperuricemic nephropathy
Qing Mao, Peng Zhang, Fengwei Lin, et al.
European Journal of Medicinal Chemistry (2025) Vol. 290, pp. 117507-117507
Closed Access
Overview of pharmacodynamical research of traditional Chinese medicine on hyperuricemic nephropathy: from the perspective of dual-regulatory effect on the intestines and kidneys
Ting Wang, Li Li, Liu Li, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Benzbromarone interferes with the interaction between Hsp90 and Aha1 by interacting with both of them
Yan Zhong, Shi Li, Zhuo Xu, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Structural Insights into the Atomistic Mechanisms of Uric Acid Recognition and Translocation of Human Urate Anion Transporter 1
Zean Zhao, Jiang Yu, Lu Li, et al.
ACS Omega (2020) Vol. 5, Iss. 51, pp. 33421-33432
Open Access | Times Cited: 26
The Extract of Sonneratia apetala Leaves and Branches Ameliorates Hyperuricemia in Mice by Regulating Renal Uric Acid Transporters and Suppressing the Activation of the JAK/STAT Signaling Pathway
Yulin Wu, Jinfen Chen, Linyun Jiang, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 23
Research progress of risk factors and early diagnostic biomarkers of gout-induced renal injury
Sheng Wang, Liyun Zhang, Dongsheng Hao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
Identification of 5-[5-cyano-1-(pyridin-2-ylmethyl)-1H-indole-3-carboxamido] thiazole-4-carboxylic acid as a promising dual inhibitor of urate transporter 1 and xanthine oxidase
Fengwei Lin, Ming Sun, Jun Gao, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115532-115532
Closed Access | Times Cited: 9
Salinomycin, a potent inhibitor of XOD and URAT1, ameliorates hyperuricemic nephropathy by activating NRF2, modulating the gut microbiota, and promoting SCFA production
Yongjun Chen, Zitao Guo, Hai-Qiao Chen, et al.
Chemico-Biological Interactions (2024) Vol. 403, pp. 111220-111220
Closed Access | Times Cited: 3
Modulation of Urate Transport by Drugs
Péter Tátrai, Franciska Erdő, Gabriella Dörnyei, et al.
Pharmaceutics (2021) Vol. 13, Iss. 6, pp. 899-899
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top